Alpine Immune Sciences, Inc.
8
0
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
37.5%
3 terminated/withdrawn out of 8 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Role: lead
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Role: lead
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Role: lead
ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD
Role: lead
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
Role: lead
A Study of ALPN-303 in Adult Healthy Volunteers
Role: lead
Cell Surface Marker Expression in Autoimmune Diseases
Role: lead
Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety
Role: lead
All 8 trials loaded